Pathophysiology of the Nervous System Flashcards
The patient with progressive diplopia and weakness with mastication (both worse at night), along with ptosis and proximal muscle weakness on examination likely has
Myasthenia Gravis
Myasthenia Gravis is characterized by
- Fluctuating weakness of certain voluntary muscles particularly those innervated by motor nuclei of the brainstem (eg. ocular and bulbar muscles)
- Progressive weakening over the course of the day or after exercise (fatigability)
- Decreased compound muscle action potential amplitude (the summed action potentials of all the muscle fibers in a motor unit) on EMG with repeated excitation
- Rapid restoration of strength of affected muscles with rest
- Improvement in strength following the administration of cholinesterase inhibitors
Myasthenia Gravis is most commonly caused by
autoantibodies against postsynaptic nicotinic acetylcholine receptors. Binding of these receptors results in blockade of the receptor’s active site, receptor internalization and degradation, and damage to the motor end plate due to complement fixation. Overall this leads to decreased numbers of functional acetylcholine receptors at the neuromuscular junction. The decrease in the number of available cation channels reduces the end plate potential following acetylcholine release. Because the threshold potential is not reached the muscle cells do not depolarize. Synaptic concentrations of acetylcholine are unaffected, unlike in botulism or Lambert-Eaton Syndrome
What changes involving postsynaptic muscle cells most likely explains the symptoms of a patient with Myasthenia Gravis
Reduced amplitude of motor end plate potential
Excitation-contraction coupling refers to the process
whereby an action potential within the muscle cell causes contraction of the muscle.
In the skeletal muscle excitation contraction coupling proceeds by
the release of calcium into the cytoplasm, which subsequently binds troponin C and induces a conformational change allowing actin and myosin to bind.
Impaired excitation coupling implies
that an action potential occurs but the skeletal muscle is unable to contract (impaired actin and myosin binding)
Myasthenia gravis is caused by a failure to
achieve the threshold for an action potential to occur
The action potential amplitude of the postsynaptic muscle cell is
determined by the properties of the cell membrane and is not affected by the quality of the stimulus at the muscle end plate.
The absolute refractory period for muscles in patients with Myasthenia Gravis is
normal
The compound muscle action potential in patients with Myasthenia Gravis
decreases with repeated excitation due to depolarization of fewer myofibers
Once the threshold voltage is exceeded at the neuromuscular end plate
an action potential propagates at a velocity determined by the particular properties of the muscle cell membrane
Education Objective: Myasthenia Gravis
- Myasthenia Gravis is an autoimmune disease that causes a decrease in the number of functional acetylcholine receptors within the neuromuscular junction. This reduces the number of postsynaptic cation channels that can open in response to acetylcholine, which reduces the amplitude of motor end plate potential and prevents muscle fiber depolarization
What are the muscarinc symptoms of cholinergic Toxicity
- Diarrhea
- Diaphoresis
- Urination
- Miosis
- Bronchospasm
- Bronchorrhea
- Bradycardia
- Emesis
- Lacrimation
- Salivation
What are the nicotinic symptoms of cholinergic toxicity
- Muscle weakness
- Paralysis
- Fasciculations
What are the symptoms of cholinergic toxicity
- Diarrhea
- Diaphoresis
- Urination
- Miosis
- Bronchospasm
- Bronchorrhea
- Bradycardia
- Emesis
- Lacrimation
- Salivation
- Muscle weakness
- Paralysis
- Fasciculations
The treatment of myasthenia gravis typically involves the use of
- a cholinesterase inhibitor
- an immunosuppressive agent
- possible thymectomy
An example of a cholinesterase inhibitor is
Pyridostigmine
Cholinesterase inhibitors function by
inhibiting the degradation of acetylcholine in the neuromuscular junction.
Selective muscarinic antagonists can be used to
reduce the side effects of cholinesterase inhibitors in sites where acetylcholine action is mediated by muscarinic receptors (ex. GI tract). Because of their selectivity these drugs improve side effects without affecting the action of cholinesterase inhibitors on skeletal muscle which uses nicotinic receptors
Examples of selective muscarinic antagonists include
- Glycopyrrolate
- Hyoscyamine
- Propantheline
Fluoxetine
is a selective serotonin reuptake inhibitor used primarily in the treatment of depression. It acts in a fashion similar to the cholinesterase inhibitors in that it prolongs the activity of the neurotransmitter on its target tissue.
Pilocarpine
is a nonselective muscarinic receptor agonist
Prazosin
is an alpha-1 adrenergic antagonist